argenx SE (NASDAQ:ARGX) Shares Bought by Bank of Montreal Can

Bank of Montreal Can lifted its position in shares of argenx SE (NASDAQ:ARGX) by 11.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,236 shares of the company’s stock after acquiring an additional 929 shares during the quarter. Bank of Montreal Can’s holdings in argenx were worth $5,680,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. FMR LLC boosted its position in argenx by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company’s stock worth $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in argenx in the 3rd quarter valued at $88,339,000. Allspring Global Investments Holdings LLC increased its holdings in argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after acquiring an additional 143,834 shares in the last quarter. Raymond James Financial Inc. acquired a new position in argenx during the fourth quarter worth $43,543,000. Finally, Jennison Associates LLC lifted its holdings in argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Up 4.4 %

NASDAQ:ARGX opened at $606.39 on Tuesday. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The stock’s fifty day moving average is $606.57 and its two-hundred day moving average is $604.95. The company has a market capitalization of $36.84 billion, a P/E ratio of -689.08 and a beta of 0.60.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Sell-side analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the subject of several research analyst reports. Citigroup restated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Truist Financial restated a “buy” rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Wells Fargo & Company increased their price objective on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Wedbush restated an “outperform” rating and issued a $715.00 price objective on shares of argenx in a report on Friday. Finally, William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $690.33.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.